問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

List

851Cases

2021-01-30 - 2022-03-31

Phase II

A phase II,Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of UB-612 Vaccine against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers

  • Condition/Disease

    COVID-19

  • Test Drug

    UB-612

Participate Sites
12Sites

Recruiting1Sites

Terminated11Sites

2018-03-05 - 2019-03-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2019-01-01 - 2023-12-31

Phase III

A phase III, randomized, open-label, controlled trial to investigate the efficacy and safety of UB-421 monotherapy as substitution for stable antiretroviral therapy in HIV-1 infected adults

  • Condition/Disease

    HIV

  • Test Drug

    UB-421

Participate Sites
12Sites

Not yet recruiting10Sites

Recruiting1Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2020-11-30 - 2021-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-12-01 - 2022-10-25

Phase II

A Multicenter, Randomized, single-blinded, Parallel-group, placebo-controlled Phase II Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally-administered TTP273 Tablets in Adult Patients with Type 2 Diabetes Mellitus (T2DM)

  • Condition/Disease

    Type 2 Diabetes Mellitus (T2DM)

  • Test Drug

    TTP273 Table

Participate Sites
4Sites

Recruiting4Sites

2021-03-01 - 2023-05-31

Phase I

A Phase Ⅰ Study of the Safety, Tolerability, Pharmacokinetics Profile, and Preliminary Efficacy of TT-00434 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    TT-00434

Participate Sites
3Sites

Not yet recruiting2Sites

Terminated1Sites

2016-04-01 - 2021-12-01

Phase I

A Phase 1 ,Randomized, Double-blind,Placebo-controlled Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of Topical BB-101(rhNEGF) for the Treatment of Diabetic Lower Leg and Foot Ulcers

  • Condition/Disease

    Treatment of Diabetic Lower Leg and Foot Ulcers

  • Test Drug

    BB-101

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2017-02-01 - 2019-04-30

Phase III

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

  • Condition/Disease

    High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD)

  • Test Drug

    RVX000222

Participate Sites
14Sites

Terminated14Sites

江晨恩
Taipei Veterans General Hospital

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2007-11-15 - 2008-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
24Sites

Terminated23Sites

Study ended1Sites

1 36 37 38 39 40 86
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB